Intracardiac Echocardiography in Atrial Flutter Ablation (FLS-ICE-R)

January 29, 2019 updated by: Pavel Osmancik, Charles University, Czech Republic

The Usefulness of Intracardiac Echocardiography in Atrial Flutter Ablation - a Randomized Study

Background: Radiofrequency ablation of typical atrial flutter present the most effective treament option in treatment of atrial flutter. Despite its high efficacy, due tovariant anatomy of cavotricuspid isthmus (CTI), i.e. location of right coronary artery, pouches, the achievment of complete bidirectional block across the CTI is sometimes chalenging. Intracardiac echocardiography (ICE) is a very usefull tool for on-line vizualization of the anatomy of the atria and also for the location of catheter position on CTI during ablation. If the routine use of ICE is associated with easier atrial fluter ablation is not clear.

Methods: One hundred consecutive patients indicated for typical atrial flutter ablation will be enrolled into the study. The patients will be randomized into group (A) ablation with use of ICE and (B) ablation without ICE. The ablation will be done in both groups by two diagnostic catheters (10-pole positioned in coronary sinus and 20-pole halo catheter positioned in the right atrium) and radiofrequency ablation catheter. The end-point of the ablation is the achievment of the bicidrectional block across the CTI. The end-points of the study are 1) the total length of the procedure, 2) the fluoroscopy time and 3) the ablation time. The safety end-point is clinically significant bleeding from the groin due to additional puncture for ICE catheter.

Discussion: We hypothesize the use of ICE wil shorten the radiofrequency energy delivery, fluoroscopy time and the length of the procedure without increasing the bleeding.

Study Overview

Status

Completed

Conditions

Detailed Description

Introduction Radiofrequency ablation (RFA) of typical atrial flutteru is the most successful method for treatment of atrial flutter. The acute (peri-procedural) efficacy is more than 95%. (1) Typical atrial flutter circuit uses the area between inferior caval vein and tricuspid anulus, so a RFA of typical flutter is performed by providing a linear lesion from inferior caval vein to tricuspid valve (this area is called as cavo-tricuspid isthmus). The recurrence of atrial flutter after ablation, which are caused by non-transmural RF lesion, are in less than 10% of cases. (2) During atrial flutter ablation, typically three electrophysiological catheters are used. Two catheters are diagnostic (one 10-pole inserted into coronary sinus and the other 20-pole inserted in the right atrium with the distal tip laterally from the cavo-ticuspid isthmus). The third is ablation catheter, inserted in the CT isthmus. The location of all three catheters is monitored by fluoroscopy and by the EP signals on catheters. Also the ablation catheter during the ablation is monitored by fluoroscopy and by the signals on the catheter.

Despite its high efficacy, the RFA of atrial flutter can be sometimes very difficult. The most difficulties are done by anatomical differences in patients. (3, 4) In the area of CTI, the rudimentary Eustachian valve can be present, which can hide the effective ablation of the CI tissue. Moreover, deep pouches can be present in the TI area, which, if unrecognized, can present the area of insufficient ablation. Both of them, Eustachian valve or pouches, are not visible by fluoroscopy. In rare cases, a complete block in the CTI are is not achieved, typically due to some anatomical difficulties. Furthermore, this anatomical obstacles can lead to prolonged fluoroscopy time (to find the location of conduction in CTI rea), more RF energy delivery and prolonged procedure time. Longer ablation time increases the risk of ablation (such as right atrial perforation). Next possible anatomical obstacle is the right coronary artery which can effective prevent sufficient ablation due to its cooling effect. (5) Intracardiac echocardiography (ICE) is done by using intracardiac echo probe. The probe is inserted in the right atrium, which allows the visualizing of the CTI area. (6, 7) ICE is used for AF ablation in some centers, but its effect has never been validated in the randomized study. The aim of our study is to assess whether routine use of ICE can lead to decrease fluoroscopy time, decrease need for RFA delivery (i.e. number of ablations) and a decrease procedure time. On the other hand, the safety endpoint will be to assess whether a routine use of ICE is not associated with higher rate of complications. We hypothesize, the use of ICE will shorten fluoroscopy, ablation and procedural time without increased number of complication

Patients and methods:

Consecutive patients indicated due to standard criteria (i.e. according to the guidelines of the European Society of Cardiology) for atrial flutter ablation will be enrolled. Exclusion criterion will be the absence of written informed content and a history of recent femoral vein thrombosis (< 6 months).

Randomization: 1 to 1 for ICE vs. non ICE RF ablation will be done routinely, as it is done in the center. In the Ice group, ICE probe will be inserted through the left femoral vein in the right atrium TH ICE will be used for the visualization of the anatomy of CTI area and the visualization of the catheter during RF delivery. In case of the non-ICE group, RFA will be done without ICE catheter, as it is done routinely now. In both groups, the diagnostic catheters (10-pole CS and 20-po in the RA) and ablation catheter will be the same. In the non-ICE group, the location of the catheters will be assessed by fluoroscopy and by signals on catheters. At the end of ablation, total fluoroscopy time, the number and length of ablation and the duration of procedure will be calculated. On the day and two weeks after the procedure, the bleeding complication will be assessed.

End-points: the major end-points will be: 1) total procedure duration (min) 2) fluoroscopy time 3) the number of ablations 4) the total duration of RF energy delivery. Major safety end-point will be complication from left femoral ICE access.

Study Type

Interventional

Enrollment (Actual)

79

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Prague, Czechia, 10034
        • Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • indication for atrial flutter ablation

Exclusion Criteria:

  • history of recent femoral vein thrombosis (within last 6 months)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Flutter ablation with intracardiac echocardiography
Atrial flutter ablation will be done using intracardiac echocardiography.
Flutter ablation will be done using intracardiac echocardiography.
Active Comparator: Flutter ablation without intracardiac echocardiography
Atrial flutter ablation will be done without intracardiac echocardiography.
Flutter ablation will be done using intracardiac echocardiography.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedure duration
Time Frame: intraoperative
The total lenght of the procedure in minuts will be measured.
intraoperative
Fluoroscopy time during ablation
Time Frame: intraoperative
The total fluoroscopy time will be measured.
intraoperative
Total ablation time
Time Frame: intraoperative
The time of radiofrequenc energy delivery during ablation will me measured.
intraoperative
Bleeding
Time Frame: 24 hours
The bleeding complication required intervention or prolonged hospitalization will be measured.
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Actual)

April 10, 2017

Study Completion (Actual)

April 10, 2017

Study Registration Dates

First Submitted

April 22, 2015

First Submitted That Met QC Criteria

April 24, 2015

First Posted (Estimate)

April 27, 2015

Study Record Updates

Last Update Posted (Actual)

January 31, 2019

Last Update Submitted That Met QC Criteria

January 29, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Study was published

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ATRIAL FLUTTER

Clinical Trials on Intracardiac echocardiography

Subscribe